Symbol="MRSN"
AssetType="Common Stock"
Name="Mersana Therapeutics Inc"
Description="Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of Antibody Drug Conjugates (ADCs) for cancer patients with unmet needs. The company is headquartered in Cambridge, Massachusetts."
CIK="1442836"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="840 MEMORIAL DRIVE, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="144126000"
EBITDA="-213975008"
PERatio="None"
PEGRatio="0"
BookValue="0.59"
DividendPerShare="0"
DividendYield="0"
EPS="-2.21"
RevenuePerShareTTM="0.322"
ProfitMargin="0"
OperatingMarginTTM="-6.65"
ReturnOnAssetsTTM="-0.485"
ReturnOnEquityTTM="-2.081"
RevenueTTM="32347000"
GrossProfitTTM="-146804000"
DilutedEPSTTM="-2.21"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="2.832"
AnalystTargetPrice="5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="57.83"
PriceToBookRatio="7.14"
EVToRevenue="32.87"
EVToEBITDA="-1.917"
Beta="1.536"
num_52WeekHigh="9.62"
num_52WeekLow="0.801"
num_50DayMovingAverage="5.39"
num_200DayMovingAverage="5.82"
SharesOutstanding="114386000"
DividendDate="None"
ExDividendDate="None"
symbol="MRSN"
open="1.23"
high="1.31"
low="1.17"
price="1.23"
volume="11814444.00"
latest_trading_day="2023-07-31"
previous_close="1.26"
change="-0.04"
change_percent="-2.7778%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="71"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Trending High"
value_analysis="Bullish Trend"
Aroon_change="FALSE"
Aroon_momentum="29"
Volume_recent_avg="5268311"
Change_recent_avg="0.04"
Delta_recent_avg="0.38"
Variance_recent_avg="0.19"
Change_ratio_recent_avg="0.6"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="29"
Aroon_momentum_negative="71"
image_negative_thumbnail_id_1="1102"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0135.jpeg"
image_negative_thumbnail_id_2="1160"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0194.jpeg"
image_neutral_thumbnail_id_1="551"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0048.jpeg"
image_neutral_thumbnail_id_2="562"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0037.jpeg"
image_positive_thumbnail_id_1="993"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0155.jpeg"
image_positive_thumbnail_id_2="985"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0147.jpeg"
image_professor_thumbnail_id_1="1204"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0038.jpeg"
image_professor_thumbnail_id_2="1180"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
